Futura Medical plc (LSE:FUM) has appointed Alex Duggan as interim CEO following recent board changes, including the departure of Angela Hildreth, who stepped down as Finance Director and COO. Duggan brings extensive leadership expertise and will oversee a strategic review focused on the company’s sales and marketing approach for its flagship product, Eroxon, which has experienced slower-than-anticipated sales growth. This review aims to sharpen commercial strategies and enhance stakeholder value, with an update anticipated by late September.
About Futura Medical
Futura Medical plc specializes in developing innovative sexual health treatments, primarily focusing on topical gel formulations. Its leading product, Eroxon, is a clinically validated topical gel designed to treat Erectile Dysfunction (ED), providing a unique over-the-counter option that acts within ten minutes. The company has secured distribution partnerships across key markets, including the US and Europe, targeting significant unmet demand in the ED segment.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.









